Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine

References

• Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:1057–574.
   Web of Science ®Google Scholar
• Murphy SM. The cost of opioid use disorder and the value of aversion. Drug Alcohol Depend. 2020;217:108382.
   PubMed Web of Science ®Google Scholar
• Chang HY, Kharrazi H, Bodycombe D, Weiner JP, Alexander GC. Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study. BMC Med. 2018;16(1):69.
   PubMed Web of Science ®Google Scholar
• Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep. 2013;61(4):1–117.
   PubMedGoogle Scholar
• Kaiser Family Foundation. Opioid overdose deaths and opioid overdose deaths as a percent of all drug overdose deaths. 2018. https://www.kff.org/other/state-indicator/opioid-overdose-deaths/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D
   Google Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008;(2):CD002207.
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–958.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;(3):CD002209.
   PubMed Web of Science ®Google Scholar
• Stein BD, Pacula RL, Gordon AJ, et al. Where is buprenorphine dispensed to treat opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties. Milbank Q. 2015;93(3):561–583.
   PubMed Web of Science ®Google Scholar
• Stein BD, Gordon AJ, Dick AW, et al. Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abuse Treat. 2015;48(1):104–111.
   PubMed Web of Science ®Google Scholar
• Ducharme LJ, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy. 2008;3:17.
   PubMed Web of Science ®Google Scholar
• Mark TL, Lubran R, McCance-Katz EF, Chalk M, Richardson J. Medicaid coverage of medications to treat alcohol and opioid dependence. J Subst Abuse Treat. 2015;55:1–5.
   PubMed Web of Science ®Google Scholar
• Bauhoff S, Stein, B.D., Pacula, R.L., Dick, A.W., Gordon, A.J., Burns, R.M., Leslie, D.L., editors. Do substance abuse policies influence opioid agonist therapies in substance abuse treatment facilities? Presented at the Addiction Health Services Research Conference; 2014;13.
   Google Scholar
• Burns RM, Pacula RL, Bauhoff S, et al. Policies related to opioid agonist therapy for opioid use disorders: the evolution of state policies from 2004 to 2013. Subst Abus. 2016;37(1):63–69.
   PubMed Web of Science ®Google Scholar
• Dick AW, Pacula RL, Gordon AJ, et al. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11. Health Aff. 2015;34(6):1028–1034.
   PubMed Web of Science ®Google Scholar
• Saloner B, Stoller KB, Barry CL. Medicaid coverage for methadone maintenance and use of opioid agonist therapy in specialty addiction treatment. Psychiatr Serv. 2016;67(6):676–679.
   PubMed Web of Science ®Google Scholar
• Oliva EM, Trafton JA, Harris AH, Gordon AJ. Trends in opioid agonist therapy in the Veterans Health Administration: is supply keeping up with demand? Am J Drug Alcohol Abuse. 2013;39(2):103–107.
   PubMed Web of Science ®Google Scholar
• Wyse JJ, Gordon AJ, Dobscha SK, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps. Subst Abus. 2018;39(2):139–144.
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Lo-Ciganic WH, Cochran G, et al. Patterns and quality of buprenorphine opioid agonist treatment in a large Medicaid program. J Addict Med. 2015;9(6):470–477.
   PubMed Web of Science ®Google Scholar
• Baxter JD, Clark RE, Samnaliev M, Aweh G, O'Connell E. Adherence to buprenorphine treatment guidelines in a Medicaid program. Subst Abus. 2015;36(2):174–182.
   PubMed Web of Science ®Google Scholar
• Saloner B, Daubresse M, Caleb Alexander G. Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population. Med Care. 2017;55(7):669–676.
   PubMed Web of Science ®Google Scholar
• Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA 2016;316(11):1211–1212.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Doyle E, Kreiner PW, et al. Prescribing patterns of buprenorphine waivered physicians. Drug Alcohol Depend. 2017;181:213–218.
   PubMed Web of Science ®Google Scholar
• Gertner AK, Robertson AG, Powell BJ, Jones H, Silberman P, Domino ME. Primary care providers and specialists deliver comparable buprenorphine treatment quality. Health Aff. 2020;39(8):1395–1404.
   Web of Science ®Google Scholar
• Mark TL, Hinde JM, Zarkin GA, Parish W, Kluckman M. Adherence to buprenorphine treatment guidelines among individuals with an opioid use disorder who have private insurance. J Subst Abuse Treat. 2020;116:108062.
   PubMed Web of Science ®Google Scholar
• Cochran G, Lo-Ciganic WH, Gellad WF, et al. Prescription opioid quality measures applied among Pennsylvania Medicaid enrollees. JMCP. 2018;24(9):875–885.
   PubMed Web of Science ®Google Scholar
• Gordon A, Lo-Ciganic WH, Cochran G, Gellad WF, Cathers T, Donohue JM. Treatment quality for buprenorphine care: the pot at the end of the rainbow. J Addict Med. 2016;10(3):210–211.
   PubMed Web of Science ®Google Scholar
• Incze MA, Kelley AT, Gordon AJ. Improving opioid use disorder treatment through quality assessment. J Gen Intern Med. 2021;36(9):2820–2822.
   Google Scholar
• National Quality Forum. Behavioral Health 2016–2017: Final Report. 2017 https://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=85831
   Google Scholar
• Fareed A, Vayalapalli S, Casarella J, Drexler K. Effect of buprenorphine dose on treatment outcome. J Addict Dis. 2012;31(1):8–18.
   PubMed Web of Science ®Google Scholar
• Hwang CS, Kang EM, Kornegay CJ, Staffa JA, Jones CM, McAninch JK. Trends in the concomitant prescribing of opioids and benzodiazepines, 2002-2014. Am J Prev Med. 2016;51(2):151–160.
   PubMed Web of Science ®Google Scholar
• Liu Y, Logan JE, Paulozzi LJ, Zhang K, Jones CM. Potential misuse and inappropriate prescription practices involving opioid analgesics. Am J Manag Care 2013;19(8):648–658.
   PubMed Web of Science ®Google Scholar
• Gellad WF, Zhao X, Thorpe CT, et al. Overlapping buprenorphine, opioid, and benzodiazepine prescriptions among veterans dually enrolled in Department of Veterans Affairs and Medicare Part D. Subst Abus. 2017;38(1):22–25.
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
   Google Scholar
• Stein BD, Dick AW, Sorbero M, et al. A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees. Subst Abus. 2018;39(4):419–425.
   PubMed Web of Science ®Google Scholar
• Manhapra A, Agbese E, Leslie DL, Rosenheck RA. Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiatr Serv. 2018;69(7):768–776.
   PubMed Web of Science ®Google Scholar
• Manhapra A, Stefanovics E, Rosenheck R. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: who gets what? Subst Abus. 2020;41(1):110–120.
   PubMed Web of Science ®Google Scholar
• Weech-Maldonado R, Morales LS, Elliott M, Spritzer K, Marshall G, Hays RD. Race/ethnicity, language, and patients' assessments of care in Medicaid managed care. Health Serv Res. 2003;38(3):789–808.
   PubMed Web of Science ®Google Scholar
• Yue D, Rasmussen PW, Ponce NA. Racial/ethnic differential effects of Medicaid expansion on health care access. Health Serv Res. 2018;53(5):3640–3656.
   PubMed Web of Science ®Google Scholar
• Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. 2019;76(9):979–981.
   PubMed Web of Science ®Google Scholar
• Wen H, Hockenberry JM, Pollack HA. Association of buprenorphine-waivered physician supply with buprenorphine treatment use and prescription opioid use in Medicaid enrollees. JAMA Netw Open. 2018;1(5):e182943.
   PubMed Web of Science ®Google Scholar
• Stein BD, Gordon AJ, Sorbero M, Dick AW, Schuster J, Farmer C. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend. 2012;123(1–3):72–78.
   PubMed Web of Science ®Google Scholar
• Clemans-Cope L, Epstein, M., Lynch, V., and Winiski, E. Rapid Growth in Medicaid Spending and Prescriptions to Treat Opioid Use Disorder and Opioid Overdose from 2010 to 2017. Washington, DC: Urban Institute; 2019.
   Google Scholar
• Turner L, Kruszewski SP, Alexander GC. Trends in the use of buprenorphine by office-based physicians in the United States, 2003–2013. Am J Addict. 2015;24(1):24–29.
   PubMed Web of Science ®Google Scholar
• Stein BD, Jones CM, Smart R, Sheng F, Sorbero M. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017–18. Drug Alcohol Depend. 2021;221:108569.
   PubMed Web of Science ®Google Scholar
• Neumann AM, Blondell RD, Azadfard M, Nathan G, Homish GG. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment. Addict Behav. 2013;38(11):2724–2728.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am J Addict. 2008;17(2):116–120.
   PubMed Web of Science ®Google Scholar
• Admon LK, Winkelman TNA, Moniz MH, Davis MM, Heisler M, Dalton VK. Disparities in chronic conditions among women hospitalized for delivery in the United States, 2005–2014. Obstet Gynecol. 2017;130(6):1319–1326.
   PubMed Web of Science ®Google Scholar
• Faherty LJ, Heins S, Kranz AM, Stein BD. Postpartum treatment for substance use disorder among mothers of infants with neonatal abstinence syndrome and prenatal substance exposure. Womens Health Rep. 2021;2(1):163–172.
   Google Scholar
• Rural Urban Continuum Codes (RUCC). In.50. https://www.networktools.nchn.org/uploads/2/7/8/5/27858331/map_rural_final_report_2018.pdf
   Google Scholar
• Cano M. Racial/ethnic differences in US drug overdose mortality, 2017–2018. Addict Behav. 2021;112:106625.
   PubMed Web of Science ®Google Scholar
• James K, Jordan A. The opioid crisis in Black communities. J Law Med Ethics. 2018;46(2):404–421.
   PubMed Web of Science ®Google Scholar
• Cano M. Drug overdose deaths among US Hispanics: trends (2000–2017) and recent patterns. Subst Use Misuse. 2020;55(13):2138–2147.
   PubMed Web of Science ®Google Scholar
• Anderson KO, Green CR, Payne R. Racial and ethnic disparities in pain: causes and consequences of unequal care. J Pain. 2009;10(12):1187–1204.
   PubMed Web of Science ®Google Scholar
• Bonham VL. Race, ethnicity, and pain treatment: Striving to understand the causes and solutions to the disparities in pain treatment. J Law Med Ethics. 2001;29(1):52–68.
   PubMed Web of Science ®Google Scholar
• Cintron A, Morrison RS. Pain and ethnicity in the United States: a systematic review. J Palliat Med. 2006;9(6):1454–1473.
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Gonin R, Baez L, Loehrer P, Pandya KJ. Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Ann Intern Med. 1997;127(9):813–816.
   PubMed Web of Science ®Google Scholar
• Freeman HP, Payne R. Racial injustice in health care. N Engl J Med. 2000;342(14):1045–1047.
   PubMed Web of Science ®Google Scholar
• Goyal MK, Kuppermann N, Cleary SD, Teach SJ, Chamberlain JM. Racial disparities in pain management of children with appendicitis in emergency departments. JAMA Pediatr. 2015;169(11):996–1002.
   PubMed Web of Science ®Google Scholar
• Green CR, Anderson KO, Baker TA, et al. The unequal burden of pain: confronting racial and ethnic disparities in pain. Pain Med. 2003;4(3):277–294.
   PubMed Web of Science ®Google Scholar
• Hoffman KM, Trawalter S, Axt JR, Oliver MN. Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between Blacks and Whites. Proc Natl Acad Sci USA. 2016;113(16):4296–4301.
   PubMed Web of Science ®Google Scholar
• Todd KH, Deaton C, D'Adamo AP, Goe L. Ethnicity and analgesic practice. Ann Emerg Med. 2000;35(1):11–16.
   PubMed Web of Science ®Google Scholar
• Sabin JA. How we fail black patients in pain. Washington, DC: Association of American Medical Colleges; 2020.
   Google Scholar
• Pro G, Camplain R, Sabo S, Baldwin J, Gilbert PA. Substance abuse treatment in correctional versus non-correctional settings: analysis of racial/ethnic and gender differences. J Health Dispar Res Pract. 2019;12(3):1–20.
   PubMedGoogle Scholar
• Cook BL, Alegria M. Racial-ethnic disparities in substance abuse treatment: the role of criminal history and socioeconomic status. Psychiatr Serv. 2011;62(11):1273–1281.
   PubMed Web of Science ®Google Scholar
• Fox AD, Anderson MR, Bartlett G, Valverde J, Starrels JL, Cunningham CO. Health outcomes and retention in care following release from prison for patients of an urban post-incarceration transitions clinic. J Health Care Poor Underserved. 2014;25(3):1139–1152.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Kinlock TW, Schwartz RP, et al. Buprenorphine treatment for probationers and parolees. Subst Abus. 2015;36(2):217–225.
   PubMed Web of Science ®Google Scholar
• Vocci FJ, Schwartz RP, Wilson ME, et al. Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners. Drug Alcohol Depend. 2015;156:133–138.
   PubMed Web of Science ®Google Scholar
• Rosenberg A, Groves AK, Blankenship KM. Comparing Black and White drug offenders: Implications for racial disparities in criminal justice and reentry policy and programming. J Drug Issues. 2017;47(1):132–142.
   PubMed Web of Science ®Google Scholar
• Ibañez GE, Agudo M, Martin SS, O’Connell DJ, Auf R, Sheehan DM. Offending behavior, drug use, and mental health among foreign-born versus U.S. born Latino criminal justice clients. J Immigrant Minority Health. 2017;19(3):674–685.
   PubMed Web of Science ®Google Scholar
• Molfenter T, Vechinski J, Taxman FS, Breno AJ, Shaw CC, Perez HA. Fostering MOUD use in justice populations: Assessing the comparative effectiveness of two favored implementation strategies to increase MOUD use. J Subst Abuse Treat. 2021;128:108370.
   PubMed Web of Science ®Google Scholar
• Vestal C. New momentum for addiction treatment behind bars. Pew Stateline Web site. https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2018/04/04/new-momentum-for-addiction-treatment-behind-bar. Published 2018. Accessed January 4, 2022.
   Google Scholar
• Justice Community Opioid Innovation Network. https://heal.nih.gov/research/research-to-practice/jcoin. Published 2021. Accessed January 4, 2022.
   Google Scholar
• Justice Community Opioid Innovation Network (JCOIN). Treatment alternatives for safe communities web site. https://www.centerforhealthandjustice.org/chjweb/tertiary_page.aspx?id=68&title=Justice-Community-Opioid-Innovation-Network-(JCOIN). Published 2018. Accessed January 4, 2022.
   Google Scholar
• Khatri UG, Howell BA, Winkelman TNA. Medicaid expansion increased medications for opioid use disorder among adults referred by criminal justice agencies. Health Aff. 2021;40(4):562–570.
   Web of Science ®Google Scholar
• Winkelman TNA, Chang VW, Binswanger IA. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open. 2018;1(3):e180558.
   PubMed Web of Science ®Google Scholar
• Hall WJ, Chapman MV, Lee KM, et al. Implicit racial/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review. Am J Public Health. 2015;105(12):e60–e76.
   PubMed Web of Science ®Google Scholar
• Cleary PD, Mechanic D, Greenley JR. Sex differences in medical care utilization: an empirical investigation. J Health Soc Behav. 1982;23(2):106–119.
   PubMed Web of Science ®Google Scholar
• Hunt K, Ford G, Harkins L, Wyke S. Are women more ready to consult than men? Gender differences in family practitioner consultation for common chronic conditions. J Health Serv Res Policy. 1999;4(2):96–100.
   PubMedGoogle Scholar
• Kandrack MA, Grant KR, Segall A. Gender differences in health related behaviour: Some unanswered questions. Soc Sci Med. 1991;32(5):579–590.
   PubMed Web of Science ®Google Scholar
• Moller-Leimkuhler AM. Barriers to help-seeking by men: A review of sociocultural and clinical literature with particular reference to depression. J Affect Disord 2002;71(1–3):1–9.
   PubMed Web of Science ®Google Scholar
• O'Brien R, Hunt K, Hart G. 'It's caveman stuff, but that is to a certain extent how guys still operate': men's accounts of masculinity and help seeking. Soc Sci Med. 2005;61(3):503–516.
   PubMed Web of Science ®Google Scholar
• Gijsbers van Wijk CM, Kolk AM, van den Bosch WJ, van den Hoogen HJ. Male and female health problems in general practice: The differential impact of social position and social roles. Soc Sci Med. 1995;40(5):597–611.
   PubMed Web of Science ®Google Scholar
• Serdarevic M, Striley CW, Cottler LB. Sex differences in prescription opioid use. Curr Opin Psychiatry. 2017;30(4):238–246.
   PubMed Web of Science ®Google Scholar
• Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv. 2019;70(2):97–106.
   PubMed Web of Science ®Google Scholar
• Rose AJ, McBain R, Schuler MS, et al. Effect of age on opioid prescribing, overdose, and mortality in Massachusetts, 2011 to 2015. J Am Geriatr Soc. 2019;67(1):128–132.
   PubMed Web of Science ®Google Scholar
• Wilder C, Lewis D, Winhusen T. Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder. Drug Alcohol Depend. 2015;149:225–231.
   PubMed Web of Science ®Google Scholar
• Ray-Griffith S, Tharp E, Coker JL, Catlin D, Knight B, Stowe ZN. Buprenorphine medication for opioid use disorder: a study of factors associated with postpartum treatment retention. Am J Addict. 2021;30(1):43–48.
   PubMed Web of Science ®Google Scholar
• National Quality Forum. A core set of rural-relevant measures and measuring and improving access to care: 2018 Recommendations from the MAP Rural Health Workgroup. 2018. https://www.networktools.nchn.org/uploads/2/7/8/5/27858331/map_rural_final_report_2018.pdf
   Google Scholar
• Wen H, Hockenberry JM, Borders TF, Druss BG. Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment. Med Care. 2017;55(4):336–341.
   PubMed Web of Science ®Google Scholar
• Saloner B, Levin J, Chang HY, Jones C, Alexander GC. Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the Affordable Care Act Medicaid expansion. JAMA Netw Open. 2018;1(4):e181588.
   PubMed Web of Science ®Google Scholar
• Ruttner L, Borck R, Nysenbaum J, Williams S. Medicaid Policy Brief: Guide to MAX Data. Washington, DC: Mathematica Policy Research; 2015.
   Google Scholar
• Byrd V, Dodd A. Medicaid Policy Brief: Assessing the Usability of Encounter Data for Enrollees in Comprehensive Managed Care across MAX 2007-2009. Washington, DC: Mathematica Policy Research; 2012.
   Google Scholar